drugset / Trial / NCT00002162
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
Treatment
Summary
To evaluate the antiviral activity and safety of two formulations of saquinavir in combination with licensed nucleoside antiretroviral drugs.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Publications
- Background Cadman J. Roche brings new formulation of saquinavir to FDA. Food and Drug Administration. GMHC Treat Issues. 1997 Apr-May;11(4/5):8.
- Background Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS. 1998 Jul 30;12(11):F103-9. doi: 10.1097/00002030-199811000-00001.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saquinavir | Small molecule | — | — |
| Background | Didanosine | Small molecule | — | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | Stavudine | Other / unclassified | — | — |
| Background | Zalcitabine | Small molecule | — | — |
| Background | Zidovudine | Small molecule | — | — |